Literature DB >> 16197974

Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers.

H Vázquez1, A Chávez-Haro, W García-Ubbelohde, R Mancilla-Nava, J Paniagua-Solís, A Alagón, C Sevcik.   

Abstract

This paper presents the first study of F(ab')2 scorpion antivenom pharmacokinetics in humans. We have studied the pharmacokinetics of an antiscorpion venom preparation (Alacramyn) in eight human healthy volunteers. The fabotherapic was administered as a 47.5 mg i.v. bolus. Blood samples were drawn at 0, 5, 15, 30, 45, 60, 90, 120, 180 and 360 min after antivenom administration. Subsequently, the volunteers made seven visits to the hospital. Four of them at 24 h intervals, one at day 10, and one at day 21. We measured antivenom plasmatic concentrations using a specific high sensitivity ELISA method for F(ab')2. The time course of F(ab')2 in serum of seven subjects was well described by a lineal combination of three exponential components; a four exponential component model was necessary to fit the eighth subject. The most significant antivenom pharmacokinetic parameters determined were: AUC(infinity)=596.9 (369.3, 891.2) mg h l(-1); V(c) = 3.1 (2.3, 4.3)l; V(ss) = 15.4 (12.8, 39.9)l; MRT = 250.0 (218.8, 310.2) h; CL = 96.6 (58.0, 139.2) ml h(-1); t(1/2,tau1) (also called t(1/2,alpha)) = 0.25 (0.13, 0.37) h; t(1/2,tau(z)) (corresponding to the slowest component) = 161.3 (141.0, 212.0) h.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16197974     DOI: 10.1016/j.toxicon.2005.08.010

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  6 in total

1.  Recent new drug approvals. Part 1: drugs with pediatric indications.

Authors:  Chasity M Shelton; Rebecca F Chhim; Michael L Christensen
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

2.  Population Pharmacokinetics of an Indian F(ab')2 Snake Antivenom in Patients with Russell's Viper (Daboia russelii) Bites.

Authors:  Geoffrey K Isbister; Kalana Maduwage; Ana Saiao; Nicholas A Buckley; Shaluka F Jayamanne; Shahmy Seyed; Fahim Mohamed; Umesh Chathuranga; Alexandre Mendes; Chandana Abeysinghe; Harindra Karunathilake; Indika Gawarammana; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

3.  Active immunity induced by passive IgG post-exposure protection against ricin.

Authors:  Charles Chen Hu; Junfei Yin; Damon Chau; John W Cherwonogrodzky; Wei-Gang Hu
Journal:  Toxins (Basel)       Date:  2014-01-21       Impact factor: 4.546

4.  Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.

Authors:  Jean-Philippe Chippaux; Leslie V Boyer; Alejandro Alagón
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-02-15

5.  Antivenom Evaluation by Electrophysiological Analysis.

Authors:  Rita Restano-Cassulini; Walter Garcia; Jorge F Paniagua-Solís; Lourival D Possani
Journal:  Toxins (Basel)       Date:  2017-02-23       Impact factor: 4.546

Review 6.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.